IPCA Laboratories
Shailesh Laul is an experienced pharmaceutical industry professional currently serving as President of Manufacturing Operations at Ipca Laboratories Limited since September 2021. Prior to this, Shailesh held significant leadership positions including Senior Vice President at Strides Shasun Limited and Vice President at Glenmark Pharmaceuticals. With a foundational role as a plant head at Glenmark Pharmaceuticals in Goa, Shailesh has demonstrated extensive expertise in manufacturing and operations throughout a career spanning over three decades, which began with an executive position at Burroughs Wellcome. Academic qualifications include a Master of Pharmacy and an MBA in Operations Management.
This person is not in any teams
IPCA Laboratories
3 followers
Ipca Laboratories Limited is engaged in pharmaceuticals business. The Company is a manufacturer and supplier of over 10 active pharmaceutical ingredients (APIs). It offers APIs, such as atenolol, hydroxychloroquine sulfate, morantel citrate, pyrantel pamoate and zaltoprofen. It offers brands, such as Zerodol, Lariago, HCQS Perinorm, Rapither, Tenoric, Lumerax, Etova, Malirid and Folitrax. Its 3c division focuses on cardiovascular and anti-diabetic markets. Its 3d division is focused on cardio-diabetic market. The Company's activa division serves the rheumatology market. Its altus division caters to the needs of intensivists, both surgical and non-surgical. Its Bionova division's focus area is dermatology. Its dynamix division focuses on cardiovascular, gastro-intestinal, anti-bacterial, pain management and respiratory sectors. It hycare division caters to the needs of cardiologists and diabetologists. Its divisions also include innova, intima, pain management, pharma and uro sciences.